Abstract
BACKGROUND Adolescents have a unique cancer profile that includes typical childhood cancers such as acute lymphoblastic leukemia (ALL) and adult-type cancers like melanoma and thyroid cancer. In Finland, adolescents above 16 years have been largely treated in adult oncology centers in contrast to many Western countries in which the minimum admittance age is 18 years. The aim of this study was to investigate characteristics, therapy and outcome of cancer in adolescents aged 16 to 17 years.
MATERIALS AND METHODS This retrospective cohort study included adolescents aged 16 to under 18 years at the time of cancer diagnosis between 2000 and 2019 in Tampere University Hospital, a regional tertiary referral center. Clinical data were retrieved from hospital medical records and included diagnosis, clinical and laboratory parameters, therapy and outcome. In addition to standard descriptive statistical analyses, the Kaplan-Meier method and Cox regression modelling were applied to study the outcome and associated factors.
RESULTS A total of 93 patients were diagnosed with a malignant tumor at the age of 16 or 17 years. Males were more often diagnosed with a cancer (62%), while non-CNS (non-central nervous system) solid cancers were the most common entities (76%) and Hodgkin lymphoma was the most common cancer diagnosis (31%). Seventy patients completed their therapy in the referral center and were followed up for a median of 5.4 years. The majority of patients were treated in the adult department (69%). Complete remission was achieved for 89% of patients, while 21% experienced tumor recurrence. The 5-year event-free survival was 65% (95% CI, 54% to 79%) and overall survival 82% (95% CI, 73% to 93%).
CONCLUSIONS The majority of cancers in adolescents of 16 to 17 years of age are solid cancers. Patient outcome in our cohort was favorable and is in line with previously published data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by Tampere University Hospital chief physician.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosure of interest. The authors report no conflicting interests.
Data Availability
The authors are unable to share the raw data due to the European Union General Data Protection Regulation (GDPR) and Finland's specific legislation on sharing of protected personal data.